Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00777036
Registration number
NCT00777036
Ethics application status
Date submitted
21/10/2008
Date registered
22/10/2008
Date last updated
13/09/2023
Titles & IDs
Public title
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Query!
Scientific title
A Phase II Study of Dasatinib Therapy in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Query!
Secondary ID [1]
0
0
2008-002260-33
Query!
Secondary ID [2]
0
0
CA180-226
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Leukemia
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Cancer
0
0
0
0
Query!
Children's - Leukaemia & Lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Dasatinib
Experimental: Cohort 1: Imatinib-resistant/intolerant CP-CML - Dasatinib 60 mg/m² tablet every day (QD) [with a maximum dose of 100 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit
OR
Dasatinib 72 mg/m² powder for oral suspension (PFOS) QD [with a maximum dose of 120 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit
Experimental: Cohort 2: Ph+ALL or AP- or BP-CML - Dasatinib 80 mg/m² tablet QD [with a maximum dose of 140 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit
OR
Dasatinib 96 mg/m² PFOS QD [with a maximum dose of 170 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit
Experimental: Cohort 3: Newly diagnosed, treatment naïve CP-CML - Dasatinib 60 mg/m² tablet QD [with a maximum dose of 100 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit
OR
Dasatinib 72 mg/m² PFOS QD [with a maximum dose of 120 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit
Treatment: Drugs: Dasatinib
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Major Cytogenetic Response (MCyR) Rate
Query!
Assessment method [1]
0
0
Major Cytogenetic Response (MCyR) rate is defined as the proportion of all treated participants who achieved a complete (0%) or partial (1%-35% Ph+ metaphases in at least 20 metaphases in bone marrow) cytogenetic response, expressed as percentage. The denominator of the MCyR response rate consists of all treated participants in Cohort 1, and the numerator is all participants in Cohort 1 achieving MCyR. 95% confidence interval was calculated by Clopper-Pearson exact method.
Query!
Timepoint [1]
0
0
From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)
Query!
Primary outcome [2]
0
0
Complete Hematologic Response (CHR) Rate
Query!
Assessment method [2]
0
0
Complete Hematologic Response (CHR) rate is defined as the proportion of all treated participants who achieve a confirmed CHR while on-study, expressed as percentage. CHR is defined as including no more than 5% blasts in bone marrow and normal white blood cell count without blasts in peripheral blood, expressed as percentage. The denominator of the CHR response rate consists of all treated participants in Cohort 2, and the numerator is all participants in Cohort 2 achieving CHR. 95% confidence interval was calculated by Clopper-Pearson exact method.
Query!
Timepoint [2]
0
0
From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)
Query!
Primary outcome [3]
0
0
Complete Cytogenetic Response (CCyR) Rate
Query!
Assessment method [3]
0
0
Complete Cytogenetic Response (CCyR) rate is defined as the proportion of all treated participants who achieve a CCyR while on-study, expressed as a percentage. CCyR rate is defined as 0% Ph+ metaphases in at least 20 metaphases in bone marrow. The denominator of the CCyR response rate consists of all treated participants in Cohort 3, and the numerator is all participants in Cohort 3 achieving CCyR. 95% confidence interval was calculated by Clopper-Pearson exact method.
Query!
Timepoint [3]
0
0
From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)
Query!
Secondary outcome [1]
0
0
Major Cytogenetic Response (MCyR) Rate in Cohort 2
Query!
Assessment method [1]
0
0
Major Cytogenetic Response (MCyR) rate was defined as the proportion of all treated participants who achieved a complete (0%) or partial (1%-35% Ph+ metaphases in at least 20 metaphases in bone marrow) cytogenetic response. The percentage of treated participants in each arm with MCyR is reported.
Query!
Timepoint [1]
0
0
From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)
Query!
Secondary outcome [2]
0
0
Complete Hematologic Response (CHR) Rate in Cohorts 1 and 3
Query!
Assessment method [2]
0
0
Complete Hematologic Response (CHR) rate defined as the proportion of all treated participants who achieve a confirmed CHR while on-study. CHR is defined as including no more than 5% blasts in bone marrow and normal white blood cell count without blasts in peripheral blood. The percentage of treated participants in each arm with CHR is reported.
Query!
Timepoint [2]
0
0
From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)
Query!
Secondary outcome [3]
0
0
Rate of Best Cytogenetic Response
Query!
Assessment method [3]
0
0
The number of participants achieving their best on-study cytogenetic response was reported as a percentage of all treated participants in that arm. (Based on >=20 Metaphases)
Query!
Timepoint [3]
0
0
From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)
Query!
Secondary outcome [4]
0
0
Time to Major Cytogenetic Response (MCyR)
Query!
Assessment method [4]
0
0
Time to MCyR is defined as the time from first dose of dasatinib until the first day MCyR criteria are met, computed only for participants whose best response is MCyR. (Based on >=20 Metaphases)
Query!
Timepoint [4]
0
0
From first dose until MCyR criteria are met (assessed up to September 2016, approximately 90 months)
Query!
Secondary outcome [5]
0
0
Duration of Major Cytogenetic Response (MCyR)
Query!
Assessment method [5]
0
0
Duration of MCyR will be computed from the first day criteria are met for MCyR until the date progressive disease (PD) is reported (or treatment is discontinued for PD) or death. Participants who neither discontinue due to PD nor die will be censored on the date of their last hematologic or cytogenetic assessment, whichever comes last. (Based on >=20 Metaphases)
Query!
Timepoint [5]
0
0
From first day criteria are met for MCyR until the date PD is reported or death (assessed up to September 2016, approximately 90 months)
Query!
Secondary outcome [6]
0
0
Time to Complete Cytogenetic Response (CCyR)
Query!
Assessment method [6]
0
0
Time to CCyR is defined as the time from first dose of dasatinib until the first day CCyR criteria are met, computed only for participants whose best response is CCyR. (Based on >=20 Metaphases)
Query!
Timepoint [6]
0
0
From first dose until CCyR criteria are met, assessed up to September 2016 (approximately 90 months)
Query!
Secondary outcome [7]
0
0
Duration of Complete Cytogenetic Response (CCyR)
Query!
Assessment method [7]
0
0
Duration of CCyR will be computed from the first day criteria are met for CCyR until the date progressive disease (PD) is reported (or treatment is discontinued for PD) or death. Participants who neither discontinue due to PD nor die will be censored on the date of their last hematologic or cytogenetic assessment, whichever comes last. (Based on >=20 Metaphases)
Query!
Timepoint [7]
0
0
From first day criteria are met for CCyR until the date of progressive disease or death (assessed up to September 2016, approximately 90 months)
Query!
Secondary outcome [8]
0
0
Progression-Free Survival (PFS) Rate at 2 Years
Query!
Assessment method [8]
0
0
PFS is defined as time from the first dosing date until the time PD is first documented by the investigator or death. Participants who die without a reported date of progression will be considered to have progressed on the date of death. Participants who neither progress nor die will be censored on the date of their last cytogenetic or hematologic assessment. The percentages of progression-free participants at 2 years are based on Kaplan-Meier estimation. Disease Progression was defined as any of the following criteria: -For CP-CML, progression to AP-CML or BP-CML while at highest tolerated dose -Increasing WBC -Loss of CHR (defined as any of the following: WBC count rises to >20.0x10^9/L; Platelet count rises to >600x10^9/L; appearance of extramedullary disease; appearance of >5% myelocytes+metamyelocytes in blood; appearance of blasts/promyelocytes in peripheral blood) -Loss of MCyR or increase in Ph+ bone marrow cells by >=30% from nadir -Death from any case during treatment
Query!
Timepoint [8]
0
0
2 years
Query!
Secondary outcome [9]
0
0
Time to Complete Hematologic Response (CHR)
Query!
Assessment method [9]
0
0
Time to CHR is defined as the time from first dose of dasatinib until the first day CHR criteria are met, provided they are confirmed 4 weeks later, computed only for participants whose best response is CHR.
Query!
Timepoint [9]
0
0
From first dose until CHR criteria are met, assessed up to September 2016 (approximately 90 months)
Query!
Secondary outcome [10]
0
0
Duration of Complete Hemotologic Response (CHR)
Query!
Assessment method [10]
0
0
Duration of CHR will be computed from the first day all criteria are met for CHR, provided they are confirmed 4 weeks later, until the date progressive disease (PD) is reported (or treatment is discontinued for PD) or death. Participants who neither discontinue due to PD nor die will be censored on the date of their last hematologic assessment.
Query!
Timepoint [10]
0
0
From first day criteria are met for CHR until date of disease progression or death (assessed up to September 2016, approximately 90 months)
Query!
Secondary outcome [11]
0
0
Disease-Free Survival Rate at 2 Years
Query!
Assessment method [11]
0
0
Disease free survival is defined as time from CCyR for participants with newly diagnosed chronic phase CML and for participants with chronic phase CML who are resistant or intolerant to imatinib (cohort 3 and cohort 1), and as time from CHR for participants with advanced phase CML and PH + ALL (cohort 2) until the time progression is first documented by the investigator or death from any cause. The percentages of disease-free participants at 2 years are based on Kaplan-Meier estimation. (CML: Chronic Myeloid Leukemia)
Query!
Timepoint [11]
0
0
2 years
Query!
Secondary outcome [12]
0
0
Overall Survival (OS) Rate at 2 Years
Query!
Assessment method [12]
0
0
OS is defined as time from the first dosing date until the time of death. All participants will be followed yearly for survival for up to 5 years after treatment discontinuation. Participants who have not died or who are lost to follow-up will be censored on the last date the participant is known to be alive. The percentages of surviving participants at 2 years are based on Kaplan-Meier estimation.
Query!
Timepoint [12]
0
0
2 years
Query!
Secondary outcome [13]
0
0
Major Molecular Response (MMR) Rate
Query!
Assessment method [13]
0
0
Molecular response was assessed using BCR-ABL transcript levels measurement by real-time quantitative polymerase chain reaction (qPCR). MMR for participants with the p210 BCR-ABL transcript variant was defined as a ratio BCR-ABL/ABL <= 10-3 or 0.1% on the international scale. In this study, ABL was used as the control-gene. For a participant with the p190 BCR-ABL transcript variant (occurring in Cohort 2 only), on-study assessments were compared to the participant's individual baseline BCR-ABL/ABL ratio and a reduction to < 0.1% or a 3-log reduction from baseline was considered an MMR.
Query!
Timepoint [13]
0
0
From date of first treatment to date of MMR (assessed up to September 2016, approximately 90 months)
Query!
Secondary outcome [14]
0
0
Complete Molecular Response (CMR) Rate
Query!
Assessment method [14]
0
0
Molecular response was assessed using BCR-ABL transcript levels measurement by real-time quantitative polymerase chain reaction (qPCR). (CMR) is defined as absence of BCR-ABL rearrangements by real-time qPCR analysis. The percentage of treated participants with CMR is reported by arm.
Query!
Timepoint [14]
0
0
From date of first treatment to date of CMR (assessed up to September 2016, approximately 90 months)
Query!
Secondary outcome [15]
0
0
Major Cytogenetic Response (MCyR) Rate up to 2 Years
Query!
Assessment method [15]
0
0
Major Cytogenetic Response (MCyR) rate is defined as the proportion of all treated participants who achieved a complete (0%) or partial (1%-35% Ph+ metaphases in at least 20 metaphases in bone marrow) cytogenetic response. The percentage of treated participants with MCyR is reported by arm.
Query!
Timepoint [15]
0
0
24 months
Query!
Secondary outcome [16]
0
0
Complete Cytogenetic Response (CCyR) Rate up to 2 Years
Query!
Assessment method [16]
0
0
Complete Cytogenetic Response (CCyR) rate is defined as the proportion of all treated participants who achieve a CCyR while on-study. CCyR rate is defined as 0% Ph+ metaphases in at least 20 metaphases in bone marrow. The percentage of treated participants with CCyR is reported by arm.
Query!
Timepoint [16]
0
0
24 months
Query!
Secondary outcome [17]
0
0
Major Molecular Response (MMR) Rate up to 2 Years
Query!
Assessment method [17]
0
0
Molecular response will be assessed using BCR-ABL transcript levels measurement by real-time qPCR. MMR for participants with the p210 BCR-ABL transcript variant is defined according to the recommendations of Hughes et al. as a ratio BCR-ABL/ABL <= 10-3 or 0.1% on the international scale proposed by the authors. The standardized baseline, as established in the IRIS trial, is taken to represent 100% on the international scale and a 3-log reduction in ratio (BCR-ABL transcripts/ABL or BCR) from the standardized baseline (MMR) is fixed at 0.1%. In this study, ABL or other housekeeping gene, will be used as the control-gene. For a participant with the p190 BCR-ABL transcript variant, on-study assessments will be compared to the participant's individual baseline BCR-ABL/ABL ratio and a reduction to < 0.1% or a 3-log reduction from baseline will be considered an MMR. The percentage of treated participants with MMR is reported by arm.
Query!
Timepoint [17]
0
0
24 months
Query!
Secondary outcome [18]
0
0
Complete Molecular Response (CMR) Rate up to 2 Years
Query!
Assessment method [18]
0
0
Molecular response will be assessed using BCR-ABL transcript levels measurement by real-time quantitative polymerase chain reaction (qPCR). (CMR) is defined as absence of BCR-ABL rearrangements by real-time qPCR analysis. The percentage of treated participants with CMR is reported by arm.
Query!
Timepoint [18]
0
0
24 months
Query!
Eligibility
Key inclusion criteria
For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com.
- CP-CML who prove resistant or intolerant to imatinib (Cohort 1)
- Ph+ ALL, AP-CML, or BP-CML who are resistant or intolerant to or who relapse after
imatinib therapy (Cohort 2)
- Newly diagnosed, treatment naive CP-CML (Cohort 3)
- Lansky or Karnofsky scale >50
- Life expectancy =12 weeks
- Adequate hepatic and renal function
- Written informed consent
- Target Population for the PK substudy must obtain written informed consent from
subject, or from parents or legal guardians for minor subjects, according to local law
and regulation
- Target Population for the PK substudy subjects must have CP-CML and be taking daily
dasatinib (tablets or PFOS) either as part of Cohort 1 or Cohort 3 of this protocol.
Patients receiving commercial dasatinib tablets outside of this protocol may be
invited to participate in this PK substudy
- Target Population for the PK substudy subjects with CP-CML who are tolerating
dasatinib tablet dose of at least 60 mg/m2 or dasatinib PFOS dose of at least 72 mg/m2
- Target Population for the PK substudy prior exposure to imatinib or other TKI therapy
is permissible
- Target Population for the PK substudy subjects must meet relevant inclusion criteria
Query!
Minimum age
1
Day
Query!
Query!
Maximum age
18
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Eligibility for potentially-curative therapy including hematopoietic stem-cell
transplantation
- Symptomatic CNS involvement (other than signs and symptoms caused by leptomeningeal
disease)
- Isolated extramedullary disease
- Prior therapy with Dasatinib
- Target Population for the PK substudy subjects participating in the PK substudy must
comply with the relevant exclusion criteria
- Target Population for the PK substudy subjects are not allowed to use proton pump
inhibitors, H2 antagonists, CYP3A4 inhibitors and inducers when entering the PK
substudy
Other inclusion/exclusion criteria may apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
20/03/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
7/12/2029
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
130
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
Local Institution - 065 - Randwick
Query!
Recruitment hospital [2]
0
0
Local Institution - Randwick
Query!
Recruitment hospital [3]
0
0
Local Institution - 069 - Westmead
Query!
Recruitment hospital [4]
0
0
Local Institution - Westmead
Query!
Recruitment hospital [5]
0
0
Local Institution - 0064 - Sth Brisbane
Query!
Recruitment hospital [6]
0
0
Local Institution - Sth Brisbane
Query!
Recruitment hospital [7]
0
0
Local Institution - 067 - North Adelaide
Query!
Recruitment hospital [8]
0
0
Local Institution - North Adelaide
Query!
Recruitment hospital [9]
0
0
Local Institution - 0066 - Parkville
Query!
Recruitment hospital [10]
0
0
Local Institution - Parkville
Query!
Recruitment postcode(s) [1]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [2]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [3]
0
0
4101 - Sth Brisbane
Query!
Recruitment postcode(s) [4]
0
0
5006 - North Adelaide
Query!
Recruitment postcode(s) [5]
0
0
3052 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Massachusetts
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New York
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Oregon
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Pennsylvania
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Texas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Washington
Query!
Country [13]
0
0
Argentina
Query!
State/province [13]
0
0
Buenos Aires
Query!
Country [14]
0
0
Argentina
Query!
State/province [14]
0
0
Cordoba
Query!
Country [15]
0
0
Brazil
Query!
State/province [15]
0
0
Parana
Query!
Country [16]
0
0
Brazil
Query!
State/province [16]
0
0
Rio Grande Do Sul
Query!
Country [17]
0
0
Brazil
Query!
State/province [17]
0
0
SAO Paulo
Query!
Country [18]
0
0
Brazil
Query!
State/province [18]
0
0
Campinas
Query!
Country [19]
0
0
Brazil
Query!
State/province [19]
0
0
Sao Paulo
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Alberta
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
British Columbia
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Nova Scotia
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Ontario
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Quebec
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Lyon
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Nantes
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Paris Cedex 12
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Paris
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Poitiers
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Frankfurt
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Hannover
Query!
Country [32]
0
0
India
Query!
State/province [32]
0
0
Gujarat
Query!
Country [33]
0
0
India
Query!
State/province [33]
0
0
Karnataka
Query!
Country [34]
0
0
India
Query!
State/province [34]
0
0
Maharashtra
Query!
Country [35]
0
0
India
Query!
State/province [35]
0
0
Tamil Nadu
Query!
Country [36]
0
0
India
Query!
State/province [36]
0
0
Tamilnadu
Query!
Country [37]
0
0
India
Query!
State/province [37]
0
0
Bangalore
Query!
Country [38]
0
0
India
Query!
State/province [38]
0
0
Kolkatta
Query!
Country [39]
0
0
India
Query!
State/province [39]
0
0
Mumbai
Query!
Country [40]
0
0
India
Query!
State/province [40]
0
0
Trivandrum
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
Bologna
Query!
Country [42]
0
0
Italy
Query!
State/province [42]
0
0
Monza (MB)
Query!
Country [43]
0
0
Italy
Query!
State/province [43]
0
0
Monza
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Roma
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Torino
Query!
Country [46]
0
0
Korea, Republic of
Query!
State/province [46]
0
0
Seoul
Query!
Country [47]
0
0
Mexico
Query!
State/province [47]
0
0
Distrito Federal
Query!
Country [48]
0
0
Mexico
Query!
State/province [48]
0
0
Jalisco
Query!
Country [49]
0
0
Mexico
Query!
State/province [49]
0
0
Nuevo Leon
Query!
Country [50]
0
0
Netherlands
Query!
State/province [50]
0
0
Rotterdam
Query!
Country [51]
0
0
Netherlands
Query!
State/province [51]
0
0
Utrecht
Query!
Country [52]
0
0
Romania
Query!
State/province [52]
0
0
Bucharest
Query!
Country [53]
0
0
Romania
Query!
State/province [53]
0
0
Sector 2
Query!
Country [54]
0
0
Russian Federation
Query!
State/province [54]
0
0
Moscow
Query!
Country [55]
0
0
Russian Federation
Query!
State/province [55]
0
0
Saint-petersburg
Query!
Country [56]
0
0
Singapore
Query!
State/province [56]
0
0
Singapore
Query!
Country [57]
0
0
South Africa
Query!
State/province [57]
0
0
FREE State
Query!
Country [58]
0
0
South Africa
Query!
State/province [58]
0
0
Gauteng
Query!
Country [59]
0
0
South Africa
Query!
State/province [59]
0
0
Western CAPE
Query!
Country [60]
0
0
Spain
Query!
State/province [60]
0
0
Barcelona
Query!
Country [61]
0
0
Spain
Query!
State/province [61]
0
0
Madrid
Query!
Country [62]
0
0
Spain
Query!
State/province [62]
0
0
Malaga
Query!
Country [63]
0
0
Spain
Query!
State/province [63]
0
0
Valencia
Query!
Country [64]
0
0
United Kingdom
Query!
State/province [64]
0
0
Central
Query!
Country [65]
0
0
United Kingdom
Query!
State/province [65]
0
0
Surrey
Query!
Country [66]
0
0
United Kingdom
Query!
State/province [66]
0
0
West Midlands
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Bristol-Myers Squibb
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to determine whether dasatinib is safe and effective in children
and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+
acute lymphoblastic leukemia (ALL), accelerated or blast phases CML who relapse after
imatinib or who are resistant or intolerant to imatinib. The side effects of this oral
investigational drug in children and adolescents will be evaluated
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00777036
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00777036
Download to PDF